185963-32-0

Usage

Uses

Used in Pharmaceutical Research:
3,5-Bis(aMinoMethyl)benzoic acid dihydrochloride is used as a building block in pharmaceutical research for the synthesis of novel molecules with potential therapeutic effects. Its unique structure allows for the creation of new drugs that can target specific receptors or enzymes, which is crucial for the development of more effective treatments.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3,5-Bis(aMinoMethyl)benzoic acid dihydrochloride is utilized as a key component in the design and synthesis of new drug candidates. Its functional groups and structural features contribute to the development of molecules that can interact with biological targets, potentially leading to the discovery of new therapeutic agents.
Used in Biochemical Research:
3,5-Bis(aMinoMethyl)benzoic acid dihydrochloride is employed in biochemical research to study the interactions between molecules and biological systems. Its presence can help researchers understand the mechanisms of action of potential drugs and how they may influence biological processes.
Used in Biotechnological Research:
In biotechnological research, 3,5-Bis(aMinoMethyl)benzoic acid dihydrochloride may be used to explore its applications in the development of new technologies and methods. Its unique properties could be harnessed to create innovative solutions in areas such as drug delivery, diagnostics, or therapeutic interventions.

Upstream product

• 29333-41-3 methyl 3,5-bis(bromomethyl)benzoate 
• 25081-39-4 methyl 3,5-dimethylbenzoate 
• 499-06-9 3,5-dimethylbenzoic acid 
• 185963-31-9 methyl 3,5-bis((N-formylformamido)methyl)benzoate 

Relevant academic research and scientific papers

GLUCOSE SENSITIVE INSULIN DERIVATIVES

The present invention relates to novel insulin derivatives and their use in the treatment or prevention of medical conditions relating to diabetes. The insulin derivatives are glucose sensitive and display glucose-sensitive albumin binding. The invention

GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES

This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates. The diboron compounds are characterized by formula (I), which is: R1-X-R2, and wherein "X" is a mono- to multiatomic linker and where R1 and R2, which may be identical or different, each represents a group of Formula (lla) or (IIb) Also described are diboron conjugates represented by the general Formula (I'), which is: R1'-X'-R2', in which either the moeities R1' or R2' or X' carry a drug that is covalently attached to the diboron compound.

164. Hydrolytical cleavage of TAR-RNA, the trans-Activation responsive region of HIV-1, by a bis(guanidinium) catalyst attached to arginine

Guanidinium compounds imitating the bis(arginine) structural motif of staphylococcal nuclease (e.g. 3) are known to be powerful catalysts for phosphoryl transfer reactions in dipolar aprotic solvents. Compound 3 also accelerates the hydrolysis of RNA (Hs

Amplifier molecules for enhancement of diagnosis and therapy

Disclosed are amplifier molecules: various organic compounds having branched structures terminating with amine groups to which pharmacologically active groups can be chemically attached. A number of MRI contrast-enhancing agents were synthesized, each comprising plural active groups, such as stable nitroxides and complexes of trivalent metal cations. Such syntheses were successfully performed using a number of amplifiers having different branched structures, demonstrating the general utility of the pertinent chemistry in the synthesis of amplifiers having any of a wide variety of pharmacologically active groups. Amplifiers were also synthesized having linkers terminating with chemically reactive groups such as isothiocyanates, which render the amplifier bifunctional: attachable to polymers, biomacromolecules, or other biocompatible entity possessing multiple reactive sites such as terminal amines. Via such chemistry, the amplifiers are attachable to monoclonal antibodies for concentration of pharmacologically active groups at a desired site in the body.